CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects
Portfolio Pulse from Jelena Martinovic
Cardiol Therapeutics Inc. (NASDAQ:CRDL) announced positive study results showing that its novel CRD-38 subcutaneous formulation, which contains cannabidiol, slowed increases in body weight and heart weight, and prevented increases in key cardiac inflammatory and remodeling markers in a model of heart failure with preserved ejection fraction (HFpEF). The study was presented at the Heart Failure Society of America Annual Scientific Meeting 2023. The findings suggest new therapeutic potential in HFpEF, a leading cause of death and hospitalization in the US and the developed world. Cardiol Therapeutics' shares traded 12.5218% higher at $0.9013 per share following the announcement.
October 10, 2023 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardiol Therapeutics' positive study results for its novel CRD-38 formulation suggest new therapeutic potential in heart failure treatment, leading to a 12.52% increase in its share price.
The positive study results for Cardiol Therapeutics' novel CRD-38 formulation suggest a new therapeutic potential in the treatment of heart failure, a leading cause of death and hospitalization in the US and the developed world. This news is highly relevant and important for the company and its investors, leading to a significant increase in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100